This article reports on the current state of published, PubMed-indexed research. It is not medical advice, and no claim here should be read as a statement that any peptide treats, cures, or heals a condition. Consult a licensed healthcare provider before using any peptide.
Why "Most Researched" Is Worth Asking
Peptide marketing tends to talk about popularity, not evidence. A compound can be widely discussed in forums and still have a thin published record, or the reverse — a peptide with decades of citations can be relatively unknown outside research circles. We track 70 peptides in our database; 65 of them have at least one indexed, peer-reviewed citation, totaling 1,095 unique citations across 1,220 indexed study records. That is the dataset behind our research evidence ranking, which orders every tracked peptide by how many published studies back it.
Ranking by study count is a transparency tool, not a quality score. A peptide can sit at the top of the list because it has been studied in dozens of animal trials and still have no completed human trial. This post walks through what the ranking actually shows, where its limits are, and how it connects to the separate — and more important — question of evidence strength.
The Top of the List
Three peptides currently sit at the top of our research hub, each with 24 indexed articles — BPC-157, TB-500, and GHK-Cu. That tie is not a coincidence of the literature — it is our index's current citation cap. Our corpus is curated and representative rather than exhaustive, capturing up to roughly 24 studies per peptide, so a count of 24 means "at or above our cap," not "exactly 24 studies exist in the world." For peptides below the cap, the count is a more literal read of what we have indexed.
Just below the cap, a second tier of four peptides each carry 21 indexed articles: Tirzepatide, Semaglutide, Retatrutide, and PE-22-28. Three of those four are GLP-1/incretin-class metabolic peptides, which reflects the sheer volume of clinical-trial activity in that drug class over the past several years — a different kind of research record than the mostly preclinical literature behind the three peptides at the top.
Volume Isn't the Same as Strength
This is the distinction the ranking alone can't show, and it's the reason we also publish a separate, hand-graded evidence-strength report. Of the 52 peptides we had enough curated literature to grade, only 10 (19%) reach our "strong" tier — FDA-approved or backed by large randomized controlled trials. 33 (63%) land at "moderate" — consistent but limited human data. The remaining 9 (17%) are "anecdotal or limited," meaning the record is preclinical or self-reported only.
In practice, this means a peptide can rank high on study count and still sit at "moderate" or lower on evidence strength, because most of its citations are reviews or animal studies rather than human trials. Count tells you how much has been published. Grade tells you what kind of evidence that publication record actually represents. Neither substitutes for the other, and neither is a claim that a peptide is effective for any specific use — both are descriptions of the literature, not endorsements.
Reviews and Preclinical Work Dominate
Across the full 1,220-record index, the publication-type breakdown explains why volume and strength diverge so often. Reviews make up 42% of indexed records (515) and preclinical research articles — animal or lab studies — another 36% (442). Clinical trials account for 17% (206) and meta-analyses for 5% (55). Added together, only about 21% of the indexed literature is human-trial grade; the other roughly 79% is reviews summarizing other work, or preclinical research that has not yet been tested in humans.
That pattern holds across nearly every peptide class we track, from healing peptides to GH secretagogues to nootropics. It is one reason we treat "most cited" and "most studied in humans" as two different rankings, even though our current ranked hub only surfaces the first one.
Five Peptides With No Indexed Research at All
Of the 70 peptides in our database, 5 have no indexed peer-reviewed research at all. We flag this deliberately rather than quietly omitting those entries from the ranking: an absence of indexed citations is not proof that a compound does nothing, and it is equally not proof that it does something. It means the published literature our index can find doesn't yet cover it. We treat that absence as a research-status fact worth stating plainly, not as a verdict in either direction.
How to Use the Ranking
If you're trying to gauge how much is actually known about a specific peptide, start at the full ranked research hub, find the compound, and open its page — each one lists every indexed citation with journal, year, and study type, so you can see directly whether the record behind a peptide is mostly reviews, mostly animal data, or includes completed human trials. Then cross-reference against the evidence-strength report if the peptide is one of the 52 we've hand-graded, since that's the closer read on whether the existing studies are strong enough to draw a conclusion from.
Either way, a study count or an evidence grade describes the literature — it does not replace a conversation with a licensed healthcare provider about your own situation, and nothing in our research library should be read as a claim that a peptide treats, cures, or otherwise guarantees any outcome.